USPTO serial 97373891
IDACIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 26, 2023
- Examiner
- STURMAN, JOSHUA M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with IDACIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Fresenius Kabi Deutschland GmbH
Bad Homburg, DE
Fresenius Kabi Deutschland GmbH
Bad Homburg, DE
Fresenius Kabi Deutschland GmbH
Bad Homburg, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott D. Woldow
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP1055 THOMAS JEFFERSON ST, NW, SUITE 400WASHINGTON, DC 20007UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Pharmaceutical preparations, namely, immunosuppressants; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and active enthesitis related arthritis, Crohn's disease, ulcerative colitis, hidradenitis colitis, hidradenitis suppurativa and non-infectious uveitis; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Biologics, namely, biological preparations for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Biologics, namely, biological preparations for the treatment of ankylosing spondylitis; Biological preparations for the treatment of and reducing signs and symptoms in adult patients with active ankylosing spondylitis; Protein therapeutics, namely, protein supplements; Pharmaceutical preparations for treating ankylosing spondylitis; Pharmaceutical preparations for the treatment of and for reducing signs and symptoms in adult patients with active ankylosing spondylitis; Pharmaceutical preparations for treating a wide variety of autoimmune diseases, illnesses and conditions | ACTIVE | Jul 1, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Fresenius Kabi Deutschland GmbH
- Other trademarks owned by Fresenius Kabi Deutschland GmbH
- Other trademarks owned by Fresenius Kabi Deutschland GmbH
- Other trademarks in Class 005
- Similar marks named IDACIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 26, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 26, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 22, 2023 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Aug 21, 2023 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Aug 2, 2023 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Aug 2, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 14, 2023 | IUAF | USE AMENDMENT FILED | — |
| Jul 14, 2023 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 17, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 22, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 22, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 2, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 13, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 7, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 7, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 12, 2022 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 12, 2022 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 12, 2022 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 5, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 27, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 25, 2022 | NWAP | NEW APPLICATION ENTERED | — |